Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I

Lancet

Volumn 361, Issue 9369, 2003, Pages 1608-1613

  Kakavanos, Revecca ^c   Turner, Chris T ^c   Hopwood, John J ^c   Kakkis, Emil D ^a   Brooks, Doug A ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LEVO IDURONIDASE; RECOMBINANT ENZYME;

ACUTE PHASE RESPONSE; ADULT; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME REPLACEMENT; HUMAN; HURLER SYNDROME; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; LONG TERM CARE; PRIORITY JOURNAL;

EID: 0037906571     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13311-9     Document Type: Article

References (32)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic basis of inherited disease. 2001;3421-3452 McGraw-Hill, New York.
2. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA. 281:1999;249-254.
3. Hopwood J.J. Enzymes that degrade heparin sulphate. Lance D.A., Lindahl U. Heparin chemical and biological properties: clinical applications. 1989;181-227 Edward Arnold, London.
4. De Duve C. From cytases to lysosomes. Fed Proc. 23:1964;1045-1054.
5. Brady R.O. The sphingolipidoses. N Engl J Med. 275:1966;312-318.
6. Holcenberg J.S. Enzyme therapy: problems and solutions. Annu Rev Biochem. 51:1982;795-812.
7. Sands M.S., Vogler C., Kyle J.W., et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest. 93:1994;2324-2331.
8. Beutler E. Enzyme replacement therapy for Gaucher's disease. Bailliere's Clin Haematol. 10:1997;751-763.
9. Grabowski G.A., Leslie N., Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 12:1998;115-133.
10. Crawley A.C., Brooks D.A., Muller V.J., et al. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest. 97:1996;1864-1873.
11. Crawley A.C., Neidzielski K.H., Isaac E.L., Davey R.C., Byers S., Hopwood J.J. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest. 99:1997;651-662.
12. O'Connor L.H., Erway L.C., Vogler C.A., et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behaviour and auditory function. J Clin Invest. 101:1998;1394-1400.
13. Kakkis E.D., McEntee M.F., Schmidtchen A., et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med. 58:1996;156-167.
14. Clarke L.A., Russell C.S., Pownall S., et al. Murine mucopolysaccharidosis type I: targeted disruption of the murine α-L-iduronidase gene. Hum Mol Genet. 6:1997;503-511.
15. Clarke L.A., Russell C.S., Matlock T., et al. Direct enzyme replacement with recombinant human iduronidase in a murine model of mucopolysaccharidosis I. Am J Hum Genet. 65:1999;A25. (abstr 124).
16. Barton N.W., Brady R.O., Dambrosia J.M., et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 324:1991;1464-1470.
17. Grabowski G.A. Current issues in enzyme replacement therapy for Gaucher disease. Drugs. 52:1996;159-167.
18. Kakkis E.D., Muenzer J., Tiller G.E., et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 344:2001;182-188.
19. Pastores G.M., Sibille A.R., Grabowski G.A. Enzyme therapy in Gaucher disease type I: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood. 82:1993;408-416.
20. Brady R.O., Murray G.J., Oliver K.L., et al. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics. 100:1997;11114.
21. Ponce E., Moskovitz J., Grabowski G. Enzyme therapy in Gaucher disease type I: effect of neutralizing antibodies to acid β-glucosidase. Blood. 90:1997;43-48.
22. Brooks D.A., King B.M., Crawley A.C., Byers S., Hopwood J.J. Enzyme replacement therapy in mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models. Biochim Biophys Acta. 1361:1997;203-216.
23. Rosenberg M., Kingma W., Fitzpatrick M.A., Richards S.M. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeated administration. Blood. 93:1999;2081-2088.
24. Brooks D.A. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab. 68:1999;268-275.
25. Brooks D.A., Hopwood J.J., King B.M. Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model. Biochim Biophys Acta. 1407:1998;163-172.
26. Turner C.T., Hopwood J.J., Bond C.S., Brooks D.A. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats. Mol Genet Metab. 67:1999;194-205.
27. Turner C.T., Hopwood J.J., Brooks D.A. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of α-L-iduronidase in immunised rats. Mol Genet Metab. 69:2000;277-285.
28. Ashton L.J., Brooks D.A., McCourt P.A., Muller V.J., Clements P.R., Hopwood J.J. Immunoquantification and enzyme kinetics of α-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients. Am J Hum Genet. 50:1992;787-794.
29. Geysen H.M., Meloen R.H., Barteling S.J. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single aminoacid. Proc Natl Acad Sci USA. 81:1984;3998-4002.
30. Durand P., Fabrega S., Henrissat B., Mornon J.P., Lehn P. Structural features of normal and mutant human lysosomal glycoside hydrolases deduced from bioinformatics analysis. Hum Mol Genet. 9:2000;967-977.
31. Brooks D.A., Fabrega S., Hein L.K., et al. Glycosidase active site mutations in human α-L-iduronidase. Glycobiology. 11:2001;741-750.
32. Henrissat B., Callebaut I., Fabrega S., Lehn P., Mornon J.P., Davies G. Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases. Proc Natl Acad Sci USA. 92:1995;7090-7094.